| pubmed-article:14604781 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14604781 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:14604781 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:14604781 | lifeskim:mentions | umls-concept:C1518294 | lld:lifeskim |
| pubmed-article:14604781 | lifeskim:mentions | umls-concept:C0025549 | lld:lifeskim |
| pubmed-article:14604781 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14604781 | pubmed:dateCreated | 2003-11-7 | lld:pubmed |
| pubmed-article:14604781 | pubmed:abstractText | Metallothionein I and II (MT-I+II) are antioxidant and tissue protective factors. We have previously shown that MT-I+II prevent oxidative stress and apoptotic cell death and are of therapeutic value in brain inflammation. However, MT-I+II are expressed in glia and it remains to be elucidated if MT-I+II can affect neurons directly. It is likely that MT isoforms could be beneficial also during neurodegenerative disorders. In this study, we have examined if MT-II affects survival and neurite extension of dopaminergic and hippocampal neurons. We show for the first time that MT-II treatment can significantly stimulate neurite extension from both dopaminergic and hippocampal neurons. Moreover, MT-II treatment significantly increases survival of dopaminergic neurons exposed to 6-hydroxydopamine (6-OHDA) and protects significantly hippocampal neurons from amyloid beta-peptide-induced neurotoxicity. Accordingly, treatment with MT-II may be of therapeutic value in neurodegenerative disorders. | lld:pubmed |
| pubmed-article:14604781 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14604781 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14604781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14604781 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14604781 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14604781 | pubmed:issn | 0006-8993 | lld:pubmed |
| pubmed-article:14604781 | pubmed:author | pubmed-author:PenkowaMilena... | lld:pubmed |
| pubmed-article:14604781 | pubmed:author | pubmed-author:BerezinVladim... | lld:pubmed |
| pubmed-article:14604781 | pubmed:author | pubmed-author:BockElisabeth... | lld:pubmed |
| pubmed-article:14604781 | pubmed:author | pubmed-author:KøhlerLene... | lld:pubmed |
| pubmed-article:14604781 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14604781 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:14604781 | pubmed:volume | 992 | lld:pubmed |
| pubmed-article:14604781 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14604781 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14604781 | pubmed:pagination | 128-36 | lld:pubmed |
| pubmed-article:14604781 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:meshHeading | pubmed-meshheading:14604781... | lld:pubmed |
| pubmed-article:14604781 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14604781 | pubmed:articleTitle | The role of metallothionein II in neuronal differentiation and survival. | lld:pubmed |
| pubmed-article:14604781 | pubmed:affiliation | Protein Laboratory, Institute of Molecular Pathology, University of Copenhagen, Panum Institute, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. | lld:pubmed |
| pubmed-article:14604781 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14604781 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14604781 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14604781 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14604781 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14604781 | lld:pubmed |
